Selected research
Industry Research
Pulmicort Industry Research Report 2026
Market perspective
The global Pulmicort market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pulmicort is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pulmicort is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pulmicort is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pulmicort include Teva, Shanghai Sine Promod, Sandoz, Mylan, Lunan Better Pharma, AstraZeneca, Synmosa Biopharma, Salix and Orion Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pulmicort market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pulmicort Market by Company
Teva
Shanghai Sine Promod
Sandoz
Mylan
Lunan Better Pharma
AstraZeneca
Synmosa Biopharma
Salix
Orion Corporation
Cosmo Pharmaceuticals
Cipla
Chiesi Farmaceutici
Pulmicort Segment by Type
Tablet and Capsule
Aerosols
Inhalation Powder
Injectable Suspension
Pulmicort Segment by Application
Inflammatory Bowel Disease Treatment
Respiratory Disease Treatment
Nose Disease Treatment
Others
Pulmicort Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmicort market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmicort and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmicort.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pulmicort manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pulmicort by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pulmicort in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet and Capsule
- Aerosols
- Inhalation Powder
- Injectable Suspension
Applications
- Inflammatory Bowel Disease Treatment
- Respiratory Disease Treatment
- Nose Disease Treatment
- Others
Companies covered
- Teva
- Shanghai Sine Promod
- Sandoz
- Mylan
- Lunan Better Pharma
- AstraZeneca
- Synmosa Biopharma
- Salix
- Orion Corporation
- Cosmo Pharmaceuticals
- Cipla
- Chiesi Farmaceutici
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pulmicort Market Size (2021-2032)
- 2.2.2 Global Pulmicort Sales (2021-2032)
- 2.2.3 Global Pulmicort Market Average Price (2021-2032)
- 2.3 Pulmicort by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablet and Capsule
- 2.3.3 Aerosols
- 2.3.4 Inhalation Powder
- 2.3.5 Injectable Suspension
- 2.4 Pulmicort by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Inflammatory Bowel Disease Treatment
- 2.4.3 Respiratory Disease Treatment
- 2.4.4 Nose Disease Treatment
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pulmicort Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pulmicort Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Pulmicort Revenue of Manufacturers (2021-2026)
- 3.4 Global Pulmicort Average Price by Manufacturers (2021-2026)
- 3.5 Global Pulmicort Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pulmicort, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pulmicort, Product Type & Application
- 3.8 Global Manufacturers of Pulmicort, Established Date
- 3.9 Global Pulmicort Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pulmicort Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Shanghai Sine Promod
- 4.2.1 Shanghai Sine Promod Company Information
- 4.2.2 Shanghai Sine Promod Business Overview
- 4.2.3 Shanghai Sine Promod Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Shanghai Sine Promod Pulmicort Product Portfolio
- 4.2.5 Shanghai Sine Promod Recent Developments
- 4.3 Sandoz
- 4.3.1 Sandoz Company Information
- 4.3.2 Sandoz Business Overview
- 4.3.3 Sandoz Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sandoz Pulmicort Product Portfolio
- 4.3.5 Sandoz Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Pulmicort Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Lunan Better Pharma
- 4.5.1 Lunan Better Pharma Company Information
- 4.5.2 Lunan Better Pharma Business Overview
- 4.5.3 Lunan Better Pharma Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lunan Better Pharma Pulmicort Product Portfolio
- 4.5.5 Lunan Better Pharma Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca Pulmicort Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 Synmosa Biopharma
- 4.7.1 Synmosa Biopharma Company Information
- 4.7.2 Synmosa Biopharma Business Overview
- 4.7.3 Synmosa Biopharma Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Synmosa Biopharma Pulmicort Product Portfolio
- 4.7.5 Synmosa Biopharma Recent Developments
- 4.8 Salix
- 4.8.1 Salix Company Information
- 4.8.2 Salix Business Overview
- 4.8.3 Salix Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Salix Pulmicort Product Portfolio
- 4.8.5 Salix Recent Developments
- 4.9 Orion Corporation
- 4.9.1 Orion Corporation Company Information
- 4.9.2 Orion Corporation Business Overview
- 4.9.3 Orion Corporation Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Orion Corporation Pulmicort Product Portfolio
- 4.9.5 Orion Corporation Recent Developments
- 4.10 Cosmo Pharmaceuticals
- 4.10.1 Cosmo Pharmaceuticals Company Information
- 4.10.2 Cosmo Pharmaceuticals Business Overview
- 4.10.3 Cosmo Pharmaceuticals Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cosmo Pharmaceuticals Pulmicort Product Portfolio
- 4.10.5 Cosmo Pharmaceuticals Recent Developments
- 4.11 Cipla
- 4.11.1 Cipla Company Information
- 4.11.2 Cipla Business Overview
- 4.11.3 Cipla Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Cipla Pulmicort Product Portfolio
- 4.11.5 Cipla Recent Developments
- 4.12 Chiesi Farmaceutici
- 4.12.1 Chiesi Farmaceutici Company Information
- 4.12.2 Chiesi Farmaceutici Business Overview
- 4.12.3 Chiesi Farmaceutici Pulmicort Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Chiesi Farmaceutici Pulmicort Product Portfolio
- 4.12.5 Chiesi Farmaceutici Recent Developments
5 Global Pulmicort Market Scenario by Region
- 5.1 Global Pulmicort Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pulmicort Sales by Region: 2021-2032
- 5.2.1 Global Pulmicort Sales by Region: 2021-2026
- 5.2.2 Global Pulmicort Sales by Region: 2027-2032
- 5.3 Global Pulmicort Revenue by Region: 2021-2032
- 5.3.1 Global Pulmicort Revenue by Region: 2021-2026
- 5.3.2 Global Pulmicort Revenue by Region: 2027-2032
- 5.4 North America Pulmicort Market Facts & Figures by Country
- 5.4.1 North America Pulmicort Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pulmicort Sales by Country (2021-2032)
- 5.4.3 North America Pulmicort Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Pulmicort Market Facts & Figures by Country
- 5.5.1 Europe Pulmicort Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pulmicort Sales by Country (2021-2032)
- 5.5.3 Europe Pulmicort Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Pulmicort Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pulmicort Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pulmicort Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pulmicort Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pulmicort Market Facts & Figures by Country
- 5.7.1 South America Pulmicort Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pulmicort Sales by Country (2021-2032)
- 5.7.3 South America Pulmicort Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Pulmicort Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pulmicort Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pulmicort Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pulmicort Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Pulmicort Sales by Type (2021-2032)
- 6.1.1 Global Pulmicort Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Pulmicort Sales Market Share by Type (2021-2032)
- 6.2 Global Pulmicort Revenue by Type (2021-2032)
- 6.2.1 Global Pulmicort Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pulmicort Revenue Market Share by Type (2021-2032)
- 6.3 Global Pulmicort Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pulmicort Sales by Application (2021-2032)
- 7.1.1 Global Pulmicort Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Pulmicort Sales Market Share by Application (2021-2032)
- 7.2 Global Pulmicort Revenue by Application (2021-2032)
- 7.2.1 Global Pulmicort Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pulmicort Revenue Market Share by Application (2021-2032)
- 7.3 Global Pulmicort Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pulmicort Value Chain Analysis
- 8.1.1 Pulmicort Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pulmicort Production Mode & Process
- 8.2 Pulmicort Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pulmicort Distributors
- 8.2.3 Pulmicort Customers
9 Global Pulmicort Analyzing Market Dynamics
- 9.1 Pulmicort Industry Trends
- 9.2 Pulmicort Industry Drivers
- 9.3 Pulmicort Industry Opportunities and Challenges
- 9.4 Pulmicort Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst